
Candel Therapeutics Inc
NASDAQ:CADL

Fundamental Analysis


Revenue & Expenses Breakdown
Candel Therapeutics Inc
Balance Sheet Decomposition
Candel Therapeutics Inc
Current Assets | 93.1m |
Cash & Short-Term Investments | 92.2m |
Other Current Assets | 983k |
Non-Current Assets | 2.8m |
PP&E | 2.4m |
Other Non-Current Assets | 324k |
Free Cash Flow Analysis
Candel Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Candel Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-33.6m
USD
|
Operating Income
|
-33.6m
USD
|
Other Expenses
|
-6m
USD
|
Net Income
|
-39.6m
USD
|
CADL Profitability Score
Profitability Due Diligence
Candel Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

Score
Candel Therapeutics Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
CADL Solvency Score
Solvency Due Diligence
Candel Therapeutics Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.

Score
Candel Therapeutics Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CADL Price Targets Summary
Candel Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CADL
is 21.42 USD
with a low forecast of 15.15 USD and a high forecast of 26.25 USD.
Dividends
Current shareholder yield for CADL is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?